TG Therapeutics (TGTX) FY2020 results: revenue $152,000, unchanged on the year
TG Therapeutics, Inc. (TGTX) reported revenue of $152,000 for fiscal 2020, the year ended 31 December 2020, unchanged on the year before. Net income was -$279 million, and diluted earnings per share $-2.42. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2021.
Revenue
$152,000
0.0% on the year
FY2016FY2020
Operating margin
-179996.1%
-111220.4% a year earlier
FY2016FY2020
Net income
-$279 million
FY2016FY2020
Diluted EPS
-$2.42
FY2016FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
0.2
0.2
0.2
0.0%
Research and development
166
154
159
+7.6%
Selling, general and administrative
108
15.0
n/a
+617.7%
Operating income
-274
-169
-174
Operating margin
-179996.1%
-111220.4%
-114736.8%
Interest expense
6.3
5.3
0.9
+19.7%
Pre-tax income
-0.3
-0.2
-0.2
Income tax
0.0
0.0
0.0
Net income
-279
-173
-173
Net margin
-183803.3%
-113730.9%
-114132.9%
Diluted EPS
-$2.42
-$1.96
-$2.30
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
-215
-133
-129
Capital expenditure
0.4
0.1
0.1
+172.5%
Free cash flow
-215
-133
-129
Free cash flow margin
-141357.9%
-87458.6%
-84878.3%
Cash from investing
-24.5
-0.7
1.2
Cash from financing
680
204
114
+232.9%
Depreciation and amortisation
0.4
0.3
n/a
+32.6%
Share-based compensation
80.3
11.3
12.9
+608.3%
Diluted shares, weighted
115m
n/a
n/a
Shares outstanding at period end
141m
109m
84m
+28.5%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
519
38.6
24.0
+1,244.9%
Debt
29.9
29.0
0.0
+3.2%
Operating lease liabilities
10.4
10.2
0.0
+1.9%
Other liabilities
66.0
85.2
59.6
-22.6%
Total liabilities and equity
626
163
83.6
+283.8%
Fixed assets
0.5
0.3
0.3
+70.6%
Goodwill
0.8
0.8
0.8
0.0%
Investments
52.0
27.8
26.9
+87.0%
Cash and equivalents
553
113
42.0
+391.3%
Other assets
18.9
21.5
13.7
-11.9%
Total assets
626
163
83.6
+283.8%
10-K for the year ended 31 December 2020, filed 1 March 2021: the filing.